The Manor Drug Company (Nottingham) Limited 00923390 false 2022-12-01 2023-11-30 2023-11-30 The principal activity of the company is wholesale and retail of human and veterinary pharmaceutical products via mail order and the internet. Digita Accounts Production Advanced 6.30.9574.0 true false false 00923390 2022-12-01 2023-11-30 00923390 2023-11-30 00923390 core:RetainedEarningsAccumulatedLosses 2023-11-30 00923390 core:ShareCapital 2023-11-30 00923390 core:CurrentFinancialInstruments 2023-11-30 00923390 core:CurrentFinancialInstruments core:WithinOneYear 2023-11-30 00923390 core:FurnitureFittings 2023-11-30 00923390 core:OfficeEquipment 2023-11-30 00923390 core:PlantMachinery 2023-11-30 00923390 bus:SmallEntities 2022-12-01 2023-11-30 00923390 bus:Audited 2022-12-01 2023-11-30 00923390 bus:FullAccounts 2022-12-01 2023-11-30 00923390 bus:SmallCompaniesRegimeForAccounts 2022-12-01 2023-11-30 00923390 bus:RegisteredOffice 2022-12-01 2023-11-30 00923390 bus:Director1 2022-12-01 2023-11-30 00923390 bus:Director2 2022-12-01 2023-11-30 00923390 bus:Director3 2022-12-01 2023-11-30 00923390 bus:PrivateLimitedCompanyLtd 2022-12-01 2023-11-30 00923390 core:ComputerEquipment 2022-12-01 2023-11-30 00923390 core:FurnitureFittings 2022-12-01 2023-11-30 00923390 core:OfficeEquipment 2022-12-01 2023-11-30 00923390 core:PlantMachinery 2022-12-01 2023-11-30 00923390 1 2022-12-01 2023-11-30 00923390 countries:EnglandWales 2022-12-01 2023-11-30 00923390 2022-11-30 00923390 core:FurnitureFittings 2022-11-30 00923390 core:OfficeEquipment 2022-11-30 00923390 core:PlantMachinery 2022-11-30 00923390 2021-12-01 2022-11-30 00923390 2022-11-30 00923390 core:RetainedEarningsAccumulatedLosses 2022-11-30 00923390 core:ShareCapital 2022-11-30 00923390 core:CurrentFinancialInstruments 2022-11-30 00923390 core:CurrentFinancialInstruments core:WithinOneYear 2022-11-30 00923390 core:FurnitureFittings 2022-11-30 00923390 core:OfficeEquipment 2022-11-30 00923390 core:PlantMachinery 2022-11-30 iso4217:GBP xbrli:pure

Company registration number: 00923390

The Manor Drug Company (Nottingham) Limited

Filleted Financial Statements

for the Year Ended 30 November 2023

 

The Manor Drug Company (Nottingham) Limited

Contents

Company Information

1

Balance Sheet

2

Notes to the Financial Statements

3 to 6

 

The Manor Drug Company (Nottingham) Limited

Company Information

Directors

Mr G A Tims

Mrs A J Cattee

Mr P Cattee

Registered office

11 Manchester Road
Walkden
Manchester
M28 3NS

Auditors

BK Plus Audit Limited
Chartered Certified Accountants & Statutory Auditors
7 Waterside Court
St. Helens
Merseyside
WA9 1UA

 

The Manor Drug Company (Nottingham) Limited

(Registration number: 00923390)
Balance Sheet as at 30 November 2023

Note

2023
£

2022
£

Fixed assets

 

Tangible assets

4

-

10,789

Current assets

 

Stocks

-

25,761

Debtors

5

11,000

40,234

Cash at bank and in hand

 

-

456,433

 

11,000

522,428

Creditors: Amounts falling due within one year

6

-

(92,969)

Net current assets

 

11,000

429,459

Net assets

 

11,000

440,248

Capital and reserves

 

Called up share capital

11,000

11,000

Retained earnings

-

429,248

Shareholders' funds

 

11,000

440,248

These financial statements have been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006.

These financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the directors have not delivered to the registrar a copy of the Profit and Loss Account.

Approved and authorised by the Board on 28 August 2024 and signed on its behalf by:
 

.........................................
Mr P Cattee
Director

   
     
 

The Manor Drug Company (Nottingham) Limited

Notes to the Financial Statements for the Year Ended 30 November 2023

1

General information

The company is a private company limited by share capital, incorporated in England and Wales.

The address of its registered office is:
11 Manchester Road
Walkden
Manchester
M28 3NS
England

These financial statements were authorised for issue by the Board on 28 August 2024.

2

Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These financial statements have been prepared using the historical cost convention.

The financial statements are prepared in sterling , which is the functional currency of the entity.

Going concern

At 1 December 2022 the directors took the decision to hive-up the trade and assets of the company to PCT Healthcare Limited, a parent undertaking, and to then cease to trade.

Accordingly the directors have not prepared the financial statements on a going concern basis.

 

The Manor Drug Company (Nottingham) Limited

Notes to the Financial Statements for the Year Ended 30 November 2023

Audit report

The Independent Auditor's Report was unqualified. The name of the Senior Statutory Auditor who signed the audit report on 28 August 2024 was Darren Leigh FCCA, who signed for and on behalf of BK Plus Audit Limited.

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the company’s activities. Turnover is shown net of sales/value added tax, returns, rebates and discounts.

The company recognises revenue when:
The amount of revenue can be reliably measured;
it is probable that future economic benefits will flow to the entity;
and specific criteria have been met for each of the company's activities.

Tangible assets

Tangible assets are stated in the balance sheet at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

Depreciation

Depreciation is charged so as to write off the cost of assets over their estimated useful lives, as follows:

Asset class

Depreciation method and rate

Plant and machinery

20% reducing balance

Fixtures and fittings

10-20% reducing balance

Computer equipment

20% reducing balance

Stocks

Stocks are stated at the lower of cost and net realisable value after making due allowance for obsolete and slow moving items.

Leases

Leases in which substantially all the risks and rewards of ownership are retained by the lessor are classified as operating leases. Payments made under operating leases are charged to profit or loss on a straight-line basis over the period of the lease.

Defined contribution pension obligation

A defined contribution plan is a pension plan under which fixed contributions are paid into a pension fund and the company has no legal or constructive obligation to pay further contributions even if the fund does not hold sufficient assets to pay all employees the benefits relating to employee service in the current and prior periods.

Contributions to defined contribution plans are recognised as employee benefit expense when they are due. If contribution payments exceed the contribution due for service, the excess is recognised as a prepayment.

 

The Manor Drug Company (Nottingham) Limited

Notes to the Financial Statements for the Year Ended 30 November 2023

3

Staff numbers

The average number of persons employed by the company (including directors) during the year, was 0 (2022 - 5).

4

Tangible assets

Fixtures and fittings
£

Plant and machinery
£

Office equipment
£

Total
£

Cost or valuation

At 1 December 2022

5,469

16,313

88,855

110,637

Disposals

(5,469)

(16,313)

(88,855)

(110,637)

At 30 November 2023

-

-

-

-

Depreciation

At 1 December 2022

4,242

15,571

80,035

99,848

Eliminated on disposal

(4,242)

(15,571)

(80,035)

(99,848)

At 30 November 2023

-

-

-

-

Carrying amount

At 30 November 2023

-

-

-

-

At 30 November 2022

1,227

742

8,820

10,789

5

Debtors

2023
£

2022
£

Trade debtors

 

-

8,076

Amounts owed by group undertakings

11,000

-

Prepayments and accrued income

 

-

9,646

Other debtors

 

-

22,512

 

11,000

40,234

 

The Manor Drug Company (Nottingham) Limited

Notes to the Financial Statements for the Year Ended 30 November 2023

6

Creditors

Creditors: amounts falling due within one year

2023
£

2022
£

Due within one year

 

Trade creditors

 

-

56,674

Amounts owed to group undertakings

-

32,495

Accruals and deferred income

 

-

3,800

 

-

92,969

7

Financial commitments, guarantees and contingencies

Amounts not provided for in the balance sheet

The total amount of contingencies not included in the balance sheet is £39,720,000 (2022 - £33,461,733).

8

Parent and ultimate parent undertaking

The company's immediate parent is W.R. Evans Healthcare Limited, incorporated in England.

 The ultimate parent is PCT Healthcare (Holdings) Limited, incorporated in England.

  These financial statements are available upon request from Companies House, Crown Way, Maindy, Cardiff CF14 3UZ